赛托瑞医疗 CYTX 深 沪
等待开盘 11-03 09:30:00 美东时间
0.2077
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 总市值 376.46万
- 52周最高 562.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 153.00
- 委 比 0.00%
- 总股本 1812.50万
- 历史最高 554625.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 153.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
10-21 20:28
Plus Therapeutics Signs Lease Agreement in Houston
An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2...
10-21 19:50
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $21
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from $20.5 to $21.
10-06 18:07
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit
CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with UnitedHealthcare insurance company, a unit of UnitedHealth Group Inc. (NYSE:
09-25 19:31
Plus Therapeutics Secures Additional $1.9M CPRIT Payment Under $17.6M Non-Dilutive Grant
Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.
09-22 19:32
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
09-18 19:57
D. Boral Capital Upgrades Plus Therapeutics to Buy, Announces $5 Price Target
D. Boral Capital analyst Jason Kolbert upgrades Plus Therapeutics (NASDAQ:PSTV) from Hold to Buy and announces $5 price target.
09-03 19:40
